CN113423465B - 治疗性的因子xii抗体 - Google Patents

治疗性的因子xii抗体 Download PDF

Info

Publication number
CN113423465B
CN113423465B CN201980090647.9A CN201980090647A CN113423465B CN 113423465 B CN113423465 B CN 113423465B CN 201980090647 A CN201980090647 A CN 201980090647A CN 113423465 B CN113423465 B CN 113423465B
Authority
CN
China
Prior art keywords
seq
ser
antibody
thr
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980090647.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN113423465A (zh
Inventor
A·格鲁伯
E·I·塔克
M·瓦利施
C·U·洛伦茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aronola Co ltd
Oregon Health and Science University
Original Assignee
Aronola Co ltd
Oregon Health and Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aronola Co ltd, Oregon Health and Science University filed Critical Aronola Co ltd
Publication of CN113423465A publication Critical patent/CN113423465A/zh
Application granted granted Critical
Publication of CN113423465B publication Critical patent/CN113423465B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201980090647.9A 2018-11-28 2019-11-27 治疗性的因子xii抗体 Active CN113423465B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862772235P 2018-11-28 2018-11-28
US62/772,235 2018-11-28
PCT/US2019/063729 WO2020113084A1 (en) 2018-11-28 2019-11-27 Therapeutic factor xii antibody

Publications (2)

Publication Number Publication Date
CN113423465A CN113423465A (zh) 2021-09-21
CN113423465B true CN113423465B (zh) 2024-12-06

Family

ID=69024611

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980090647.9A Active CN113423465B (zh) 2018-11-28 2019-11-27 治疗性的因子xii抗体

Country Status (5)

Country Link
US (1) US12134657B2 (https=)
EP (1) EP3886982A1 (https=)
JP (1) JP7478149B2 (https=)
CN (1) CN113423465B (https=)
WO (1) WO2020113084A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023531315A (ja) * 2020-07-03 2023-07-21 シーエスエル・イノベーション・プロプライエタリー・リミテッド 第ｘｉｉ因子抗原結合タンパク質の高濃度製剤
CN116265945B (zh) * 2022-01-05 2025-12-09 上海迈晋生物医药科技有限公司 抗凝血药物的生物学活性检测方法
EP4729546A1 (en) * 2023-06-16 2026-04-22 Jiangsu BioJeTay Biotechnology Co., Ltd. Antibody specifically recognizing factor xiia and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101102819A (zh) * 2004-12-23 2008-01-09 Csl百灵有限公司 血栓的形成和/或稳定化的预防

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
WO2003013423A2 (en) 2001-08-05 2003-02-20 Gvg, Inc. Antithrombotic agent
ES3005912T3 (en) * 2011-07-22 2025-03-17 Csl Behring Gmbh Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
CN202179824U (zh) 2011-07-22 2012-04-04 北京美亚视景创恒科技有限公司 数字健身设备集群系统
WO2014089493A1 (en) 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
BR112016029624A2 (pt) * 2014-06-18 2017-10-24 Csl Behring Gmbh terapia usando um inibidor do fator xii em um distúrbio neurotraumático

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101102819A (zh) * 2004-12-23 2008-01-09 Csl百灵有限公司 血栓的形成和/或稳定化的预防

Also Published As

Publication number Publication date
US12134657B2 (en) 2024-11-05
CN113423465A (zh) 2021-09-21
JP2022513437A (ja) 2022-02-08
US20220089776A1 (en) 2022-03-24
EP3886982A1 (en) 2021-10-06
WO2020113084A1 (en) 2020-06-04
JP7478149B2 (ja) 2024-05-02

Similar Documents

Publication Publication Date Title
DK2373691T3 (en) ANTI-FXI ANTIBODIES AND PROCEDURES FOR USE
JP7366988B2 (ja) 抗凝固因子ｘｉ抗体
US9574013B2 (en) Antibodies against factor XII and uses thereof
TWI743039B (zh) 凝血因子ｘｉ抗體及使用方法
JP7500662B2 (ja) 抗第ＸＩ／ＸＩａ因子抗体による処置法
ES2698950T3 (es) Anticuerpos capaces de unirse al Factor XI de coagulación y/o a su forma activada, Factor XIa, y usos de los mismos
JP2022172275A (ja) Ｍａｓｐ－２依存性の補体活性化を阻害するための組成物
JP6253578B2 (ja) 阻害性抗第ｘｉｉ／ｘｉｉａ因子モノクローナル抗体及びそれらの使用
US7771720B2 (en) Humanized PAI-1 antibodies
JP7022081B2 (ja) 抗凝固因子ｘｉ抗体
CN116333147A (zh) 用于治疗各种疾病和病症的抑制masp-3的组合物和方法
CN113423465B (zh) 治疗性的因子xii抗体
JP2024544057A (ja) 血栓塞栓性疾患を予防及び／又は治療する方法
ES2773682T3 (es) Método para el diagnóstico y tratamiento del cáncer usando anticuerpos que se unen al inactivador de C1, proteína C reactiva y/o componente C4 del complemento
HK40062102A (en) Therapeutic factor xii antibody
HK40062102B (zh) 治疗性的因子xii抗体
BR112021014313A2 (pt) Anticorpos humanizados inovadores contra o fator xi que tem efeitos anti-trombóticos e anti-inflamatórios e usos dos mesmos
TW202405022A (zh) 與抗因子ｘｉ／因子ｘｉａ抗體之組合療法
BR112018069283B1 (pt) Anticorpos monoclonais contra o sítio ativo de fator xi e usos dos mesmos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40062102

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant